Back to top

Alnylam Targets Down Syndrome-Linked Alzheimer’s With New Phase 2 Mivelsiran Trial

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals (ALNY) is launching a Phase 2 study ti...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)